Search the GHTC website

Global health R&D delivers for Wyoming

US government investment in global health R&D has delivered

$3.3 million
to Wyoming research institutions
Wyoming's top USG-funded global health R&D institutions

Wyoming's top USG-funded global health R&D institutions

University of Wyoming
$3.3 million

Wyoming's top areas of global health R&D by USG funding

Global health R&D at work in Wyoming

University of Wyoming (UW) researchers are conducting basic research to better understand how HIV-specific antibodies produce an immune response to infection. They are examining the structures of a category of proteins called glycoforms and how that structure impacts the ability of the antibodies to block transmission in mucosal tissue, the area where initial HIV infection mainly occurs. Their findings could inform efforts to develop vaccines and monoclonal antibody therapies. Since the beginning of the AIDS epidemic, at least 40 million people have died of AIDS. Sub-Saharan Africa remains the most severely affected, as the region is home to two-thirds of all people living with HIV globally.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: 2011, Charlotte Raymond Photography for International AIDS Vaccine Initiative (IAVI)